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peridone. Methods: Cost-utility analysis was performed using a Markov model. 
The primary outcome was ICER/QALY. Oral risperidone, oral paliperidone and 
long-acting risperidone were selected as comparators. The basic components of 
the model include probabilities of relapse, individual hazard ratios for non-com-
pliance by medication type and switch of treatment probabilities. Specific utili-
ties for each health state were considered. Among relevant costs, reflecting payer’s 
perspective, drug acquisition costs, monitoring costs, costs of relapses, follow-up 
care and adverse events were considered. Results: Long-acting paliperidone 
reached ICER of EUR 16,233/QALY compared to oral risperidone, EUR 15,058/QALY 
to oral paliperidone and EUR 335/QALY to long-acting risperidone. The robustness 
of the model was supported by one-way deterministic analysis and probabilistic 
sensitivity analysis, which gave stable results. Long-acting paliperidone was cost 
effective in 97% of the simulations compared to oral risperidone. Long-acting pali-
peridone treatment gained incremental 0.903 QALYs on average compared to oral 
risperidone. ConClusions: The treatment of schizophrenia using long-acting 
paliperidone is associated with increased QALYs. It reduces incidence of adverse 
events, results in better prevention of relapses and can be considered a cost-effective 
treatment in the Czech Republic.
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objeCtives: Switching to vortioxetine (a new antidepressant) after inadequate 
response to selective serotonin re-uptake inhibitor/serotonin–norepinephrine 
reuptake inhibitor (SSRI/SNRI) resulted in a significant and clinically relevant 
improvement versus agomelatine (REVIVE head-to-head clinical study) and also 
better efficacy over sertraline, venlafaxine and bupropion (indirect comparison). 
The aim of this study is to assess the Finnish cost-utility of vortioxetine versus 
these antidepressants in patients who switch due to inadequate response to 
previous treatments. Methods: A one year cost-utility analysis was performed 
using a decision tree model for the second line and a Markov model for subse-
quent lines of MDD treatment. Undiscounted payer and societal perspectives were 
considered. Three health-states (depression, remission, recovery) and two treat-
ment phases (2-month acute, 6-month maintenance) were defined. The relative 
efficacy of antidepressants was derived from the REVIVE trial and indirect com-
parisons at 2 months. Efficacy in subsequent treatment steps was derived from the 
STAR*D study. Adverse events and their consequences were included and derived 
from REVIVE, indirect comparisons, literature and expert opinion. Utilities were 
derived from REVIVE and the literature using Finnish preference weights. Finnish 
costs in 2013/2014 value were considered. Sensitivity analyses were conducted to 
assess the robustness of the findings. Results: Vortioxetine was dominant from 
the payer’s and societal perspective versus all comparators. It was projected to 
result to QALY gain of 0.013, 0.017, 0.025 and 0.028, and € 223 (€ 1074), € 128 (€ 957), € 110 
(€ 720) and € 238 (€ 1390) direct (total) annual cost saving compared to agomelatine, 
bupropion, venlafaxine and sertraline respectively. These results were confirmed to 
be robust in several sensitivity analyses. ConClusions: Vortioxetine dominated 
agomelatine, bupropion, venlafaxine and sertraline in Finland and appears to be a 
relevant treatment option for MDD patients who need a therapy switch.
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objeCtives: To estimate the cost-effectiveness of paliperidone palmitate (PLAI), 
a once-monthly long-acting injectable (LAI) atypical antipsychotic, compared 
to the most common antipsychotic strategies in France. Methods: A Markov 
model was developed to simulate the progression of a cohort of schizophrenic 
patients through four health states (stable treated, stable non-treated, relapse 
and death) and up to three lines of treatment. PLAI was compared to risperidone 
LAI (RLAI), aripiprazole LAI (ALAI), olanzapine LAI (OLAI), haloperidol decanoate 
(HLAI) and oral olanzapine (OO). Costs, quality-adjusted-life-years (QALYS) and 
number of relapses were assessed over five years based on three-month cycles, 
and discounted at 4%, from a health insurance perspective. Patients were sup-
posed to be stabilised after a clinical decompensation and entered the model into 
an initiation phase, followed by a relapse prevention phase in case of success. 
In the prevention phase, relapse rates were derived from hospitalisation risks 
based on French real-life data in order to capture the adherence effects. Safety 
and utility data were derived from international publications. Costs came from 
French health insurance databases and publications. Robustness of results was 
assessed through deterministic and probabilistic sensitivity analyses. Results: 
PLAI was the less costly LAI and associated with an incremental cost-effectiveness 
ratio (ICER) of € 1,988/QALY gained and € 2,267/relapse avoided versus OO. RLAI 
and PLAI were associated with the highest number of QALYs (ICER of € 2,421,386/
QALY gained between PLAI and RLAI). PLAI dominated all other LAIs in terms of 
relapse but OLAI. Nevertheless, PLAI was highly cost-effective versus OLAI (ICER of 
€ 1,575,217/relapse avoided). ConClusions: This analysis is the first to assess the 
cost-effectiveness of antipsychotics based on French observational data. PLAI was 
found to be the least expensive LAI antipsychotic from French payer perspective. 
Oral therapies were less expensive but associated with lower levels of QALYs and 
more relapses compared to all atypical LAIs.
£6000 for all scenarios and a 100% probability of being cost-effective at a willingness 
to pay of £20,000 per QALY. Verbal therapy appeared more cost-effective than art 
therapy with a cost per QALY below £1000 but there was considerable uncertainty 
in the decision and a sizeable probability (20%) that art therapy was dominant. 
In neither comparison was the art therapy intervention similar to that employed 
in England and Wales, furthermore in the wait list comparison patients were not 
explicitly diagnosed with non-psychotic mental disorders. As such, the generalis-
ability of the results to practice in England and Wales is uncertain. ConClusions: 
Art therapy appears cost effective versus wait-list but of uncertain value compared 
with verbal therapy. Confirmatory studies are required to allow more definitive 
statements to be made.
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objeCtives: To estimate the cost-effectiveness of augmentation of SSRI antidepres-
sant therapy with either lithium or an AAP in TRD, defined as failure to respond to 
two or more antidepressants. Methods: CENTRAL, EMBASE, MEDLINE, PsycINFO 
and NHS Economic Evaluation Database (NHS EED) were searched from inception 
to August 2011. Additional data were obtained from manufacturers. Systematic 
reviews of the economic and quality of life (QoL) literature were executed. Studies 
were assessed, independently by two reviewers, for quality against predefined cri-
teria. A de novo probabilistic economic model was developed to synthesise the 
available data on costs and clinical effectiveness from UK NHS perspective; time 
horizon 1-year (8 weeks of acute treatment and 10 months of maintenance treat-
ment). Results: Four economic evaluations (none directly addressing the review 
question) and 17 QoL studies were identified and summarised in narrative reviews. 
Model results indicate that augmentation of an SSRI with lithium dominates aug-
mentation with AAP (i.e. Results in cost savings of £905 per person per year and 
generates more health benefits, estimated to be 0.03 quality-adjusted life-years). 
However, sensitivity analyses showed that the model was highly sensitive to 
changes in acute treatment efficacy (response and remission) or discontinuation. 
The model was not sensitive to changes in other parameters. ConClusions: Cost-
effectiveness analyses suggest that augmentation with lithium is less expensive 
and more effective than augmentation with AAP. However, the uncertainty in the 
clinical estimates of discontinuation and treatment response is reflected in the 
model results. An RCT comparing the two augmentation strategies, reporting rel-
evant outcomes, including QoL, is needed.
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objeCtives: Computerised cognitive behaviour therapy (cCBT) forms a core com-
ponent of stepped psychological care within primary care in the UK and other 
countries. However, the existing clinical effectiveness evidence for cCBT comes 
from developer-led trials and independent research is needed which evaluates the 
clinical and cost-effectiveness of cCBT. Methods: A cost-effectiveness analysis 
was undertaken comparing two cCBT software packages, free-to-use MoodGYM 
and a commercial pay-to-use Beating the Blues (BtB), in addition to usual 
general practitioner care (UGPC), with UGPC alone, for the treatment of depressed 
adults. The analysis was based on data collected on the Randomised Evaluation of 
the Effectiveness and Acceptability of Computerised Therapy (REEACT). REEACT 
was a large (n= 691), pragmatic multicentre study, independently conducted in 
a primary care setting. Outcomes were assessed using EQ-5D and used to esti-
mate quality-adjusted life-years (QALYs). Resource use and costs were esti-
mated from a NHS and Personal Social Services perspective. Scenario analyses 
were performed to determine the impact on cost-effectiveness of alterna-
tive assumptions, and uncertainty was characterised using cost-effectiveness 
acceptability curves. Results: BtB was both more expensive and generated lower 
QALYs than UGPC alone (dominated) and MoodGYM yielded lower QALYs but at 
lower cost, resulting in an ICER of £6,933 per additional QALY for UGPC alone 
versus MoodGYM. UGPC alone was the most cost-effective intervention in the 
majority of scenario analyses, and the intervention most likely to be cost-effec-
tive at a £20,000 per QALY threshold (probabilities ranging across scenarios from 
0.545 to 0.619). ConClusions: Our findings indicate that commercially-produced 
products were no more effective than free-to-use cCBT programmes. Importantly, 
neither BtB or MoodGYM appeared cost-effective compared to UGPC alone. Practice 
recommendations such as those offered by NICE and other countries supporting 
the use of cCBT within stepped models of care for depression will need to be 
reconsidered in light of these results.
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objeCtives: The number of patients with schizofrenia in the Czech Republic 
amounts annually to approximately 126,000. Schizophrenia causes signifi-
cant increases in mortality, shortening life expectancy by 25 years compared to 
the general population which implies high disease burden. The aim was to esti-
mate the cost-effectiveness of long-acting paliperidone in the treatment with 
schizofrenia compared to oral risperidone, oral paliperidone and long-acting ris-
